---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020460"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T15:55:57.645101+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BriaCell raises $5.0M in registered direct offering with warrants; director participates

## Summary
- Gross proceeds of $5.0M from sale of 2,402,935 shares (or pre-funded warrants) and warrants for additional 2,402,935 shares.
- Combined purchase price: $2.00/share for institutional investors; $2.215/share for a director of the company.
- Warrants exercisable at $2.11/share, beginning 6 months from issuance, expiring in 5 years.
- Net proceeds to fund working capital and Phase 3 pivotal study in advanced breast cancer.
- Closing occurred May 17, 2024; placement agent A.G.P./Alliance Global Partners received 7% fee and 50,000 warrants.

## SEC filing metadata
- accession: 0001493152-24-020460
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/0001493152-24-020460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020460
- JSON: https://secwatch.observer/filing/0001493152-24-020460.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020460.txt

## Key facts
- Material Agreements
  BriaCell Therapeutics Corp. entered into Securities Purchase Agreements with certain investors valued at Gross proceeds of $5,000,000 from sale of shares and warrants (effective 2024-05-14).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: Gross proceeds of $5,000,000 from sale of shares and warrants
  - Effective: 2024-05-14
  source text: On May 14, 2024, BriaCell Therapeutics Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain investors (collectively the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/0001493152-24-020460-index.htm
- Material Agreements
  BriaCell Therapeutics Corp. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Cash fee of 7.0% of gross proceeds; Placement Agent Warrants for 50,000 shares at $2.321 per share (effective 2024-05-14).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: Cash fee of 7.0% of gross proceeds; Placement Agent Warrants for 50,000 shares at $2.321 per share
  - Effective: 2024-05-14
  source text: In connection with the Offering, on May 14, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/0001493152-24-020460-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.